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Abstract: Background: Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses
caused by type I/IVb reactions against mainly Culicoides bites. The vaccination of IBH-affected horses with
equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMVTT) induces IL-5-specific
auto-antibodies, resulting in a significant reduction in eosinophil levels in blood and clinical signs.
Objective: the preclinical and clinical safety of the eIL-5-CuMVTT vaccine. Methods: The B cell responses
were assessed by longitudinal measurement of IL-5- and CuMVTT-specific IgG in the serum and plasma of
vaccinated and unvaccinated horses. Further, peripheral blood mononuclear cells (PBMCs) from the same
horses were re-stimulated in vitro for the proliferation and IFN-γproduction of specific T cells. In addition,
we evaluated longitudinal kidney and liver parameters and the general blood status. An endogenous
protein challenge was performed in murine IL-5-vaccinated mice. Results: The vaccine was well tolerated
as assessed by serum and cellular biomarkers and also induced reversible and neutralizing antibody titers
in horses and mice. Endogenous IL-5 stimulation was unable to re-induce anti-IL-5 production. The CD4+
T cells of vaccinated horses produced significantly more IFN-γ and showed a stronger proliferation
following stimulation with CuMVTT as compared to the unvaccinated controls. Re-stimulation using
E. coli-derived proteins induced low levels of IFNγ+CD4+ cells in vaccinated horses; however, no
IFN-γ and proliferation were induced following the HEK-eIL-5 re-stimulation. Conclusions: Vaccination
using eIL-5-CuMVTT induces a strong B-cell as well as CuMVTT-specific T cell response without the
induction of IL-5-specific T cell responses. Hence, B-cell unresponsiveness against self-IL-5 can be
bypassed by inducing CuMVTT carrier-specific T cells, making the vaccine a safe therapeutic option for
IBH-affected horses.
Vaccines 2020, 8, 213; doi:10.3390/vaccines8020213 www.mdpi.com/journal/vaccines
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1. Introduction
Insect bite hypersensitivity (IBH) is a type I/IVb hypersensitivity to mainly Culicoides salivary
gland proteins characterized by the induction of IgE, activation of mast cells and basophils and
late-phase eosinophil accumulation in the skin [1,2]. The key molecule in the differentiation, activation,
and survival of eosinophils is Interleukin-5 (IL-5) [3–6]. We recently presented IL-5 to be a suitable
target for treating IBH-affected horses and developed a therapeutic vaccine consisting of equine
IL-5 (eIL-5) linked to virus-like particles (VLPs). The vaccine induces IL-5-specific auto-antibodies,
thereby significantly reducing the levels of eosinophils and clinical signs of IBH [7,8]. VLPs are
supra-molecular structures consisting of one or more structural viral proteins, but lacking the genetic
information of a virus, representing an important safety aspect of VLPs. The immune system strongly
responds to VLPs due to their key immunological features such as their particulate structure, size,
repetitive surface, and pathogen-associated molecular patterns (PAMPs), which makes VLPs a useful
tool for vaccine development [9–11]. Coupling a non-immunogenic soluble self-protein to a highly
immunogenic VLP forms hapten-carrier-like conjugates. In that way, the non-immunogenic hapten
part becomes “visible” to the immune system and receives T cell help as a bystander signal derived
from the foreign immunogenic VLP carrier [12–14]. As a result, T cell-dependent long-lasting IgG
antibody responses are developed against both the carrier VLP and the hapten self-molecule, although
hapten-specific T cell responses are absent. In the case of a hapten being a self-molecule, it is of
particular importance that no auto-reactive T cells are generated upon vaccination, thus protecting
from auto-immunity. In contrast, self-reactive B cells are less problematic, as B cells are tightly
regulated by T cells and the latter are strictly selected by positive and negative selections during
thymic T cell repertoire development, creating a self-tolerant T cell repertoire [15,16]. Taken together,
safety aspects of vaccines targeting self-molecules demand different safety requirements for B and T
cells. Important for the control of auto-reactive B cell responses are the reversibility of the IgG antibody
response and the lack of their activation through endogenous protein other than by the vaccine. For T
cells, safety requirements for vaccination against self-proteins are stricter, as the vaccine should not
induce any auto-reactive T cells. Here, we want to shed light on the B and T cell safety of anti-self
vaccines including various other clinical safety parameters in horses being vaccinated against the
self-protein IL-5 for several consecutive years using the eIL-5-CuMVTT vaccine.
2. Materials and Methods
2.1. Mice
Female C57BL/6 mice were purchased from Harlan, Horst. The mice were kept under specified
pathogen-free conditions. All the animal experimentation was approved by the Swiss cantonal
veterinary authorities.
2.2. MIL-5-Qβ Vaccine
The cloning, expression, purification, and vaccine production of mouse IL-5 (mIL-5) and Qβ was
previously described [17].
2.3. Endogenous Challenge in Mice
The mice were subcutaneously immunized three times in bi-weekly intervals (days 0, 14, and 28)
using mIL-5-Qβ. Two weeks after the last vaccination, the mice were intravenously challenged using
either the vaccine or the mIL-5 protein alone or PBS (Gibco, Thermo Fisher Scientific, NY, USA) as
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control (day 42). The bleeding was performed at baseline, one day prior to the challenge and two
weeks after the challenge (day 0, 41, and 56).
2.4. MIL-5-Specific ELISA
The IL-5-specific antibodies were semi-quantified by ELISA in serum on day 0, 41, and 56,
as previously described [17]. However, using mIL-5 produced by HEK cells (NRC CNRC, Montreal,
Canada), HEK-mIL-5 (see below section ‘recombinant proteins for stimulation and ELISA’). The OD50
was calculated for evaluation of the antibody titer.
2.5. Horses and Vaccination
All the study horses were client-owned IBH-affected horses and participated in the clinical studies
of Evax AG (Switzerland) and therefore had been vaccinated with eIL-5-CuMVTT in accordance with
the previously published clinical studies [7,8] (Figure S1). All the horse owners signed informed
consent. All the animal experimentation was approved by Swiss cantonal veterinary authorities,
ethical approval code 25152, 28711, 29065, 27530, 29968. The vaccine was produced as described
earlier [7].
In 2018 and 2020, blood samples were collected from 34 Icelandic horses that participated
in two clinical trials starting in 2015 (group 1,2) or 2017 (group 3,4) and had received the active
vaccine for the 1st (8 horses), 2nd (9 horses), 3rd (11 horses), 4th (4 horses), or 5th (2 horses) year,
respectively. Data of the 3rd, 4th, and 5th year-vaccinated horses were combined into 3–5 year samples.
Control blood was collected from unvaccinated Icelandic horses, i.e., 7 placebo-vaccinated IBH-affected
and 9 non-vaccinated healthy horses. IFN-γ production: All the above-described horses were included
into an intracellular IFN-γ measurement of the re-stimulated equine peripheral blood mononuclear
cells (PBMCs). However, six of these horses with an active vaccine for the 3rd (2 horses), 4th (3 horses),
or 5th (1 horse) year had to be excluded from the common analysis due to the high assay background
already in the medium control samples, most likely due to assay medium contamination in all samples
from these horses. Unfortunately, the experiment could not be repeated due to the shutdown of the
university’s flow cytometry facility during the corona crisis. Therefore, these six horses are shown
separately (CD4+ Figure 1b; CD8+ Figure 1d) from the other horses (CD4+ Figure 1a; CD8+ Figure 1c),
and in order to correct for the background, a quotient of the stimulant divided by the medium
control values is shown instead. Proliferation: In total, there were 21 horses, i.e., 10 unvaccinated
(placebo) control horses and 11 vaccinated horses that received an active vaccine for the 1st (5 horses),
2nd (4 horses), or 3rd (2 horses) year. Also, due to the shutdown of the university laboratories including
flow cytometry facility, we could not include any more horses that were planned for the measurement
in 2020.
2.6. Recombinant Proteins for Stimulation and ELISA
E. coli-eIL-5 and CuMVTT were produced in the E. coli strain C2566 (New England Biolabs,
MA, USA) and purified and refolded, as previously described [7,8,18]. HEK-eIL-5 or HEK-mIL-5
are mature eIL-5 (mature Interleukin-5, equus caballus; UniProt O02699) or mature mIL-5 (mature
Interleukin-5, mus musculus; UniProt P04401), respectively, and were in silico codon optimized,
N-terminally connected to a mouse Igκ signal sequence, and C-terminally connected to a GGC-linker
followed by a Strep-tag and a stop codon. The resulting fragment was synthesized (IDT Genomics,
USA) and integrated into the expression vector pCB14 by isothermal cloning. The HEK 293T cells were
grown to an 80% confluency and transfected with polyethylenimine (PEI) (PEI Max 40K, Polysciences,
USA) at a PEI to DNA ratio of 2.5. The eIL-5 and mIL-5-containing supernatants were harvested
after 5 days and purified via the Strep-tag by Strep-Tactin (IBA Lifesciences, Göttingen, Germany)
column, respectively. Murine Granulocyte-macrophage colony-stimulating factor (GM-CSF) is mature
mGM-CSF (mature Granulocyte-macrophage colony-stimulating factor, mus musculus; UniProt P01587)
and was codon-optimized and flanked with 5′NdeI and 3′XhoI restriction sites in silico. The fragment
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was synthesized (IDT Genomics, USA) and integrated into the expression vector pET42b(+), resulting in
mGM-CSF, which is followed by a hexa His-tag and an in-frame stop codon and was expressed in the
E. coli strain BL21DE03 (New England Biolabs, MA, USA). The overnight cultures were grown at 37 ◦C
and diluted with LB medium containing 50 mg/L of kanamycin. The cultures were induced by adding
IPTG to a final concentration of 1 mM at OD600 values of 0.6, followed by 4 h incubation. The culture
was centrifuged and the resulting pellet re-suspended in 2 mM EDTA, 0.5% Triton X-100, 50 mM
TrisHCl, pH 8.0. Inclusion bodies were prepared and solubilized in 6 M GdmCl, 10 mM DTT, 50 mM
TrisHCl, pH 8.0. The murine GM-CSF was purified via the His-tag by a NiNTA (NiNTA Superflow,
Qiagen, MD, USA) column and eluted with an elution buffer 6 M GdmCl, 0.5 M NaCl, 0.5 M Imidazole,
20 mM TrisHCl, pH 5.9. The eluate was diluted with the elution buffer to 1 mg/mL, mixed 1:1 with 2 M
GdmCl, 50 mM Tris, pH 8.0 and subsequently dialyzed.
2.7. Isolation of Equine PBMCs
Blood was collected from the jugular vein in heparin-tubes (Greiner) two weeks after the annual
boost. The peripheral blood mononuclear cells (PBMCs) were isolated by the density gradient using
Biocoll, as described previously [19]. The PBMCs were cultured in RPMI (Thermo Fisher Scientific,
NY, USA), supplemented with L-Glutamine, HEPES, 10% inactivated horse serum or FBS (Merck,
Germany), 100 U/mL Penicillin, 100 µg/mL Streptomycin (Merck), 1mM Sodium pyruvate (Merck),
1% non-essential amino acids (Merck), MEM vitamins (Merck), and 2-Mercaptoethanol (0.05 mM).
2.8. Intracellular IFN-γMeasurement of Re-Stimulated Equine PBMCs
The 5 × 106 cells/well-isolated PBMCs were seeded in 12-well plates. For the quantification of the
intracellular IFN-γ of the CD4+ and CD8+ T cells, the cells were stimulated for 18 h at 37 ◦C with 1µg/mL
E. coli-eIL-5, HEK-eIL-5, CuMVTT, Tetanus Toxoid (Astarte Biologics, WA, USA) as a positive control for
the antigen-specific response, or E. coli-mGM-CSF as an irrelevant protein stimulus. Alternatively, the cells
were left unstimulated as a negative control. Of note, not all stimuli were tested for all horses. After 14 h
stimulation, Brefeldin A (Sigma, MO, USA) (10 µg/mL) was added to all wells and phorbol 12-myristate
13-acetate (Sigma, MO, USA) (PMA; 25 ng/mL) and ionomycin (Sigma, MO, USA) (I; 1µg/mL) were added
to one well with unstimulated cells as a positive control (data not shown). Four hours later, the cells were
harvested and washed (centrifugation for 10 min at 600xg at 4 ◦C). Staining was performed with mouse anti
equine CD4-FITC (1:40, clone CVS4, Biorad, USA) and mouse anti-equine CD8β-PE (1:10, clone HT14A,
Washington State University, WA, USA), then they were labeled with the Zenon R-Phycoerythrin mouse
IgG1 labeling kit (Thermo Fisher Scientific, NY, USA) and the LIVE/DEADTM Fixable Near-IR dead-cell
stain kit (1:300, Thermo Fisher Scientific, NY, USA) for 15 min at 4 ◦C. Cells were washed, fixed and
permeabilized by Fixation/Permeabilization solution (BD Biosciences, Allschwil, Switzerland) for 30 min
at 4 ◦C. Cells were washed with 1 × BD Perm/Wash and stained with mouse anti-equine IFN-γ-Alexa 647
(1:500, clone 38-1, Wagner Laboratory, Cornell University, USA) for 30 min at 4 ◦C. The cells were acquired
with a FACS Canto II flow cytometer (BD Biosciences, Allschwil, Switzerland). The compensation was
calculated by the FACSDiva software with single-stained compensation controls. The gating strategy is
shown for the tetanus toxoid stimulation (Figure S2). The results are shown as percentages of CD4+CD8-
or CD8+CD4- cells producing IFN-γ following re-stimulation with different stimulants.
2.9. Cell Proliferation of Re-Stimulated Equine PBMCs
Isolated PBMCs were stained with the CellTraceTM violet cell proliferation kit (Thermo Fisher
Scientific, USA) for the detection of proliferated cells following 7 days of re-stimulation. Up to 40 × 106
PBMCs were stained according to the manufacturer’s instructions; 2 × 106 stained PBMCs in 1 mL
medium/well were seeded in 24-well plates. The cells were stimulated for 7 days at 37 ◦C with
1µg/mL of E. coli-eIL-5, HEK-eIL-5, CuMVTT, Tetanus Toxoid (NiNTA Superflow, Qiagen, MD, USA)),
E. coli-mGM-CSF, or ConA (Sigma, MO, USA) (data not shown), or left unstimulated as a negative
control. Of note, not all stimuli were tested for all horses. At day 7, the cells were harvested and stained
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in one step with mouse anti-equine CD4-FITC, mouse anti-equine CD8β-PE, and the LIVE/DEAD Near
IR, as described. The gating strategy is shown for tetanus toxoid stimulation (Figure S3). The results
are shown as the percentage of proliferating CD4+CD8- or CD8+CD4- following re-stimulation with
different stimulants.
2.10. Stimulation of Equine PBMCs with Resiquimod and Detection of Specific IgG
The isolated PBMCs (1 × 106 cells/well) were seeded in 1 mL complete medium in 24-well plates.
The cells were stimulated with 5 µg/mL Resiquimod (Sigma, MO, USA) [20], cells were incubated for
7 days at 37 ◦C and the supernatant was collected for IgG detection.
2.11. IL-5 and CuMVTT Specific IgG ELISA
An antigen-specific IgG ELISA was carried out, as described by Jonsdottir et al. [21], except that
the plates were coated with E. coli-eIL-5, HEK-eIL-5 or CuMVTT. The IgG subclasses, IgG1, IgG4/7,
and IgG5, were measured in plasma and sera at a 1:100 dilution, whereas the total IgG was measured in
the undiluted supernatant of PBMCs. The IgG subclass-specific antibodies were previously described [22].
The quantification of total antigen-specific IgG in sera was described by Fettelschoss-Gabriel et al. [8].
Additionally, the supernatant was examined for the total IgG against Tetanus Toxoid (Schweizerisches
Serum und Impfinstitut, Bern, Switzerland, [23]).
2.12. Avidity of IL-5-Specific IgG
For an avidity evaluation of IL-5-specific IgG after the yearly booster of the 1st, 2nd, and 3rd
year, maxisorp 96-well ELISA plates (Nunc) were coated with purified E. coli-eIL-5 (5 mg/L) in a
coating buffer (0.1 M NaHCO3, pH 9.6) overnight at 4 ◦C. The plates were blocked with Superblock
(Thermo Fisher Scientific, NY, USA) for 2 h at RT. Two sets of pre-diluted 1:10 sera were transferred to
the ELISA plates and further serially diluted (three-fold dilutions) in Superblock. After 2 h incubation
at RT, the sera were washed off and the plates washed 3 times for 5 min either with 7 M urea in PBST
(PBS + 0.05% tween 20) or PBST only. All the plates were incubated with HRP-conjugated anti-equine
IgG (1:2000, Jackson ImmunoResearch, PA, USA) at RT for 30 min before being developed with TMB
(Thermo Scientific, USA) for 1 min. The absorbance was measured at 450 nm (OD450) on a Tecan Spark
10M spectrophotometer (Tecan, Grödig, Austria). The OD50 titer is described as the reciprocal serum
dilution, where OD450 reaches the half maximum OD [8]. Titers below 10 (and including 10) were
considered as background. The avidity data are described as the avidity index (AI) and refer to the
ratio of the same dilution treated with and without 7 M urea (AI = OD (dilution x) + urea/OD (dilution
x) no urea).
2.13. Clinical Chemistry and Hematology Analysis
The liver and kidney parameters were monitored in the serum of clinical study horses to
observe the changes upon vaccinations. A differential blood analysis was measured by EDTA blood.
The parameters were assessed in the placebo year; the 1st, 2nd, and 3rd treatment year; before the
first vaccination (in January, February, or March; S = spring); and at the season end (September;
A = autumn). The serum and blood were analyzed by IDEXX Diavet, Freienbach, Switzerland.
2.14. Statistical Analysis
The statistical analysis and preparation of graphs were performed with GraphPad Prism 7.
A Shapiro–Wilk normality test showed that the data sets were not normally distributed (data not
shown), and therefore we used non-parametric tests. The statistical tests were performed as indicated
in the Figures. A statistical result is only indicated when statistically significant. Considered to be
statistically significant were p-values lower than 0.05: * p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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3. Results
3.1. No Induction of Auto-Reactive Peripheral Blood T Cells Upon Vaccination
To investigate if a long-term vaccination with eIL-5-CuMVTT induces IL-5 reactive T cells, PBMCs
from horses vaccinated for 1, 2, and 3–5 years (vaccination and bleeding regimen in Figure S1) and from
unvaccinated controls were re-stimulated in vitro with E. coli-eIL-5, HEK-eIL-5, and the VLP CuMVTT.
In addition, the cells were also treated with tetanus toxoid as a positive control for antigen-specific T
cell responses, as all the horses were previously vaccinated against tetanus by their owners and also
with an unrelated E. coli expressed E. coli-mGM-CSF as an irrelevant protein. The T cell activation was
quantified by the frequency of intracellular IFN-γ-positive CD4+ and CD8+ T cells following treatment
with different stimulants. In addition, the proliferation of CD4+ and CD8+ T cells of the same PBMCs
from part of the horses were treated with the same stimulants.
3.1.1. IFN-γ Production
The IFN-γ production following any stimulation was compared to the control of unstimulated cells
(medium) and vaccinated to unvaccinated horses within the stimulant. The frequency of IFN-γ-producing
CD4+ T cells was significantly increased within PBMCs from vaccinated horses following stimulation
with CuMVTT and the tetanus toxoid, whereas only for tetanus toxoid unvaccinated horses showed a
significantly increased IFN-γ frequency. Of note, the response to the tetanus toxoid varied due to varying
time points for the tetanus vaccination. For stimulation with the unrelated E. coli-produced mGM-CSF
and E. coli-mGM-CSF, we found a small but significantly increased frequency of IFN-γ-producing CD4+
T cells when comparing the E. coli-mGM-CSF and medium-stimulated vaccinated horses. This suggested
that E. coli-derived traces within the purified protein might lead to the unspecific re-stimulation
of PBMCs. In line with this, the re-stimulation with E. coli-produced CuMVTT led to significantly
increased IFN-γ frequencies in unvaccinated horses comparing the medium and CuMVTT re-stimulation.
Therefore, we performed re-stimulation of eIL-5 not only with E. coli-eIL-5 but also with HEK-eIL-5.
As expected, E. coli-eIL-5 led to a statistically significantly increased frequency of IFN-γ-producing
CD4+ T cells, while there was no difference for HEK-eIL-5 re-stimulation either when comparing to
medium or comparing the vaccinated and unvaccinated (Figure 1a). Six horses from the 3–5 years group
were analyzed separately due to the medium control background, and they showed comparable results
(Figure 1b), nonetheless reflecting the results in Figure 1a nicely. Furthermore, the treatment duration
and numbers of vaccine injections, either in the 1st vaccination year after the last booster (blue circles),
2nd (red circles), or 3–5 (green) vaccination years, did not influence the frequency of IFN-γ-producing
CD4+ T cells upon HEK-eIL-5 re-stimulation or any other stimulants (Figure 1a,b).
The difference between the vaccinated and control horses was less obvious for the CD8+ T cells, but in
general correlated well with the frequencies observed for the CD4+ T cells (Figure 1c). Comparably, the six
separately analyzed horses also showed similar results (Figure 1d), and also no influence of vaccination
duration was found (Figure 1c,d).
3.1.2. Proliferation
Similar results were obtained as well for the proliferation of CD4+ (Figure S4a) and CD8+
(Figure S4b) T cells, thus reflecting the IFN-γ-results.
IgG. In parallel to the T cell re-stimulation experiments, a fraction of the PBMCs were stimulated
with the TLR-7 agonist resiquimod in order to show the potential reactivity of the PBMCs and to
demonstrate the relevance of HEK-eIL-5. The specific IgG was measured in the cell supernatant by
ELISA and indeed not only E. coli-eIL-5 (Figure S4c) but also HEK-eIL-5 (Figure S4d) showed increased
levels of IL-5-specific IgG antibodies in the vaccinated horses (blue, 1 year) when compared to the
unvaccinated control (grey). Moreover, the HEK-eIL-5-specific IgG antibody determination led to a
lower variability in the unvaccinated horses. CuMVTT-specific IgG were also found to be significantly
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increased in the vaccinated horses (Figure S4e). In contrast, the tetanus-specific IgG did not differ
between the two groups (Figure S4f).Vaccines 2020, 8, x 4 of 16 
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medium control, HEK-eIL-5, E. coli-eIL-5, CuMVTT, tetanus toxoid (TetaTox), or E. coli-mGM-CSF of 
PBMCs from unvaccinated (−) control horses (grey) and 1st (blue), 2nd (red), or 3–5 (green) year 
vaccinated (+) horses. (A,B) CD4+ T cells, percentages of IFNγ-producing cells (A), percentages of 
IFNγ-producing cells of quotient stimuli/medium (B). (C,D) CD8+ T cells, percentages of IFNγ-
producing cells (C), percentages of IFNγ-producing cells of quotient stimuli/medium (D). Values of 
individual horses with median on a log scale. Differences between the unvaccinated (−) controls and 
vaccinated (+) horses were analyzed with the Mann-Whitney U test. The medium unstimulated cells 
were compared to the stimulated cells by the Wilcoxon matched pairs rank with Bonferroni 
correction. There are significant differences between the unstimulated and stimulated cells within 
groups indicated with a for the controls and b for vaccinated horses. Medium corrected samples were 
analyzed by Kruskal–Wallis with Dunn’s multiple comparison. * p < 0.05; **p < 0.01; ***p < 0.001; ****p 
< 0.0001. 
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Figure 1. No auto-reactive CD4+ and CD8+ T cells upon the in vitro re-stimulation of peripheral blood
mononuclear cells (PBMCs) from the vaccinated and control horses. In vitro re-stimulation using the
medium control, HEK-eIL-5, E. coli-eIL-5, CuMVTT, tetanus toxoid (TetaTox), or E. coli-mGM-CSF of PBMCs
from unvaccinated (−) control horses (grey) and 1st (blue), 2nd (red), or 3–5 (green) year vaccinated (+)
horses. (A,B) CD4+ T cells, percentages of IFNγ-producing cells (A), percentages of IFNγ-producing cells of
quotient stimuli/medium (B). (C,D) CD8+ T cells, percentages of IFNγ-producing cells (C), percentages of
IFNγ-producing cells of quotient stimuli/medium (D). Values of individual horses with median on a log
scale. Differences between the unvaccinated (−) controls and vaccinated (+) horses were analyzed with
the Mann-Whitney U test. The medium unstimulated cells were compared to the stimulated cells by the
Wilcoxon matched pairs rank with Bonferroni correction. There are significant differences between the
unstimulated and stimulated cells within groups indicated with a for the controls and b for vaccinated
horses. Medium corrected samples were analyzed by Kruskal–Wallis with Dunn’s multiple comparison.
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
3.2. Anti-Self Antibody Induction Is Rob st, Reversible, Neutralizing, and Not Auto-Induced
To assess the potential of endogenous IL-5 to boost the previously established vaccine-induced
IL-5-specific antibody responses and thus have the risk for uncontrolled anti-self antibody production,
a challenge experiment in mice was conducted. To this end, the mice received three immunizations
of mIL-5-VLP to establish anti-IL-5 antibody titers. Two weeks after the third vaccination, the mice
were challenged either with soluble mIL-5 mimicking the endogenous protein, with mIL-5-VLP as
a positive control and PBS as a negative control. Serum was collected before vaccination, prior to
the challenge, and two weeks post challenge in order to compare the IL-5-specific titers which were
measured by ELISA.
The vaccination with mIL-5-VLP induced strong mIL-5 antibody titers in all animals detected
on day 41. As expected, mice that were challenged with the mIL-5-VLP significantly increased their
anti-mIL-5 antibody titers detected at day 56, whereas the mice challenged with PBS or with soluble
mIL-5 alone showed no increase in mIL-5-specific titers (Figure 2a).
To test for the reversibility of the specific antibody responses in horses, anti-eIL-5 IgG antibody
titers were followed before and after eIL-5-CuMVTT immunizations in three consecutive years during
several time points throughout the study, with the final time point prior to the annual booster of the
fourth year. The vaccination regimen is shown in Figure S1.
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In the first year, anti-IL-5 IgG antibody titers were successfully induced upon two vaccinations
and a mid-season booster injection and dropped towards the end of the season. In the consecutive
two years, a single booster was sufficient to raise the anti-IL-5 antibody titers. Of note, the specific
IgG antibody levels almost returned to pre-immune levels after each season. The peak antibody titers
measured after the booster injections in the following years were found to achieve levels of specific
IgG close to the peak titers observed after two initial vaccinations. The serological analysis showed
that the specific antibody responses were reversible within one year and could be efficiently boosted
once a year by a single injection (Figure 2b).Vaccines 2020, 8, x 9 of 16 
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Figure 2. Longitudinal IL-5-specific IgG antibo y titer including neutralization and avidity without
self-induction. (A) Endogenous self-induction. IL-5-specific IgG antibody titers were measured in serum
by the ELISA of mice following vaccination with mIL-5-VLP applied on days 0, 14, and 28 and an
endogenous-mimicry challenge with either mIL-5-VLP (filled black), PBS (open), or mIL-5 alone (filled
grey), applied on day 42. Individual antibody titers are per group (n = 5) with mean and SEM. Significances
were obtained by a 2-way ANOVA; multiple comparisons with paired t-tes s are at different time points
within groups. (B) Longitudinal anti-IL-5 IgG. Antibody titer reversibility shown by the course of
IL-5-specific antibody titers in horses of a 3-year clinical study; IL-5-specific IgG antibody titers (mean +/−
SEM) were measured in the serum of horses over three years at different time points. Arrows indicate
vaccine injections. The graph contains parts of data of Figures 1 and 2, of Fettelschoss-Gabriel et al.
2019, Allergy. (C) Course of eosinophils in the blood during three IBH seasons: placebo-treated season
(grey circle, n = 13), first year (black circle, n = 13), and second year (black tri ngle, n = 11) vaccination
season. Part of th data of Figure 2c is published in Fettelschoss-Gabriel et al. 2019, All rg . The mean and
SEM are shown, statistical analysis was performed by the Friedman test. (D) Avidity of the IL-5-specific
IgG antibodies of eight horses after the yearly booster in the 1st, 2nd, and 3rd year. The avidity index is
plotted for individual horses in each year with the mean and SEM; the statistical analysis was performed by
the Friedman test (*) followed by a multiple comparison test (n.s.). ** p < 0.01; *** p < 0.001; **** p < 0.0001.
In order to show that the anti-IL-5 antibody production in all vaccination years was equally
efficient, we show in the same horses the eosinophil levels in the blood in the placebo-treated year and
first and second treatment year. When compared to the placebo year, equally significantly reduced
eosinophil levels in the blood were een in the first vaccination year, with a total of three injections,
and in the second vaccin tion year with the single b oster (Figure 2c).
We further analyzed the total IgG antibodies and determined the avidity of IL-5-specific IgG in
eight horses after the first, second, and third year by performing a titration ELISA in the presence and
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absence of 7 M Urea as the chaotropic agent. The treatment by urea dissociated all the low avidity
antibodies, whereas the high avidity antibodies remain bound. The avidity index indicated a trend
towards an increase in avidity in the second vaccination year compared to the first year, which was
maintained in the third year (Figure 2d).
3.3. IgG Antibody Subclasses
In parallel to the PBMCs stimulation experiments, IL-5- and CuMVTT-specific IgG subclasses
were assessed in plasma.
The IL-5- and CuMVTT-specific antibodies induced by the vaccine were mostly of the subclass
IgG1 and IgG4/7 and, to a lower extent, IgG5. All the vaccinated horses produced significant levels of
IgG1, IgG4/7, and IgG5 against E. coli-eIL-5 (Figure 3a), HEK-eIL-5 (Figure 3b), and CuMVTT (Figure 3c)
in the plasma as compared to the controls. The non-vaccinated control horses did not show any
meaningful antibody level tested for E. coli-, HEK-IL-5, or CuMVTT.
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(ICs) in the blood. During steady state, ICs are cleared by erythrocytes or platelets (dependent on the 
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Figure 3. Specific IgG subclasses levels in plasma at the time of the T cell assays. (A,B,C) Subclasses in
plasma at the same time as the T cell assays. E. coli-eIL-5- (A), HEK-eIL-5- (B), and CuMVTT- specific
(C) IgG1, IgG4/7, and IgG5 were measured in the plasma of unvaccinated (−) control horses (grey),
first (blue), second (red), or third (green) year vaccinated (+) horses by ELISA. OD405 value of the
individual horses with the mean and SEM for each group. The Mann–Whitney U test was used to
compare the difference between the groups within each subclass. (D,E) IgG1 and IgG4/7 were measured
in the serum of vaccinated horses against CuMVTT (D) and HEK-eIL-5 (E) by ELISA, mean with SEM.
The time points measured: before the initial vaccinations (V), after the initial vaccinations (A), at the
time of the annual boost at the 1st year (V1), 2–4 weeks after the boost at the 1st year (A1), at the time of
the annual boost at the 2nd year (V2), 2–4 weeks after the boost at the 2nd year (A2), at the time of the
annual boost at t e 3rd year (V3), and 2–4 weeks after the boost at t e 3rd year (A3). Black arrows
indicate the initial vac inations and the gray arrows the e rly booster. ** p < 0.01; *** p < 0.0001.
As IgG1 and IgG4/7 were found to be the main IgG subclasses induced by vaccination with the
eIL-5-CuMVTT assessed in plasma, the IL-5- and CuMVTT-specific IgG1 and IgG4/7 were measured
in serum at diff rent time points: 1st year before vaccination (V), fter the 2nd vaccination (A),
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when boosted (V1), and after the boost (A1); 2nd year when boosted (V2), and after the boost (A2);
and 3rd year when boosted (V3), and after the boost (A3). CuMVTT- (Figure 3d) and HEK-IL-5-specific
(Figure 3e) IgG1 and IgG4/7 are shown. After the two initial vaccinations (V), the horses had high
levels of CuMVTT- and IL-5-specific IgG1 and IgG4/7. From the time of the 2nd vaccination until the
boost, the IL-5-specific IgG1 levels decreased more than the IgG4/7 levels. For CuMVTT, the surrogate
marker, the annual boost led to similar levels of CuMVTT-specific IgG1 and IgG4/7 as after the initial
vaccinations. In contrast, the levels of IL-5-specific IgG1 and IgG4/7 seemed to decline over time.
3.4. No Induction of Immune Complex Disease and Good General Health Status
IL-5-specific antibodies bind to their target protein IL-5 and thus can form immune complexes (ICs)
in the blood. During steady state, ICs are cleared by erythrocytes or platelets (dependent on the species) in
the liver and spleen via the complement system in order to prevent depositions in the circulation that
could damage the kidney [24]. For the six liver and nine kidney parameters measured, no deviation was
observed over three years of vaccination compared to the normal values observed in the placebo-treated
horses. Over the course of the three-year study, we observed only two outliers—i.e., in one horse for the
Serum Amyloid A (SAA) value (most likely the horse had an acute infection), and in one horse with
increased symmetric dimethylarginine (SDMA). Both values were within the normal range in a repeated
measurement two to four weeks later (Figure 4 and Figure S5).
In addition to the clinical chemistry assessment, a blood differential analysis followed the numbers
of the leukocyte, neutrophil, and erythrocyte counts as well as the hematocrit (%) and hemoglobin
(mmol/L). There were no meaningful differences observed at any time after vaccination compared to
the baseline or placebo treatment (Figure S6).
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Figure 4. Immune complex disease by liver and kidney parameters. Liver (A) and kidney (B) parameters
were measured in spring (S) and autumn (A) in the placebo year and the 1st (V1), 2nd (V2), and 3rd
(V3) treatment year. Values of the individual horses are shown with mean and SEM. Statistical a alysis
was performed by Kruskal–Wallis with Dunn’s multiple comparison. Statistical significance is only
indicated when at least one value was outside of the norm.
4. Discussion
Vaccinating IBH-affected horses with eIL-5-CuMVTT was shown to be an effective way to improve
the clinical symptoms of the disease [7,8]. Here we present data that support the safety of the IL-5 vaccine
and allow drawing conclusions regarding the tolerability and toxicity of the vaccine, which induced
IL-5-specific IgG antibodies without us observing any adverse events throughout the longitudinal
study. The therapeutic vaccine aims at the activation of IL-5-specific B cells to produce antibodies that
neutralize endogenous IL-5 and subsequently reduce numbers of eosinophils, promoting clinical benefit
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of IBH-related symptoms in horses. In line with previously published data in mice on a VLP-based
vaccine targeting IL-1β in a model for type two diabetes [25], our vaccine does not induce IL-5-specific
T cells in horses, whereas the IL-5-specific B cells do receive bystander T cell help from VLP-specific T
cells in order to generate long-lived and reversible anti-IL-5 IgG antibodies.
B cell unresponsiveness towards auto-proteins is limited by the absence of auto-reactive T cells.
The latter are strictly regulated by positive and negative selection eliminating TCRs with a high affinity
to self-MHC or self-MHC plus self-antigen. In contrast, B cells are mainly regulated by the presence or
absence of antigen-specific T cell help in combination with the soluble antigen. Because of this efficient
negative selection of the T cells, there is no need for the B cells to undergo such a strict selection [26].
During B cell maturation, self-reactive B cells are negatively selected in the bone marrow; however,
some B cells can escape negative selection when undergoing an additional light chain editing and
subsequently leave the bone-marrow into peripheral tissues [27–29]. Unless T cell help is provided for a
cognate antigen, the thymus-independent (TI) stimulation of B cells can only induce short-lived IgM
antibodies without the induction of memory responses. A long-lived IgG production by plasma cells
including memory responses always requires antigen-specific T cells and is called thymus-dependent
(TD) antibody response [30,31]. The formation of hapten-carrier complexes can bypass this dogma
by providing bystander T cell help from the immunogenic carrier to the non-immunogenic but
antigenic hapten [12–14]. As B and T cells differ in their development, the safety criteria for those cells
differ, especially when targeting auto-proteins [32,33]. One important safety requirement for B cell
responses when targeting auto-proteins is that the endogenous target protein, in this case endogenous
IL-5, should not boost the vaccine-induced anti-IL-5 antibody response. The challenge experiment in
mIL-5-VLP-vaccinated mice showed that only a challenge with mIL-5-VLP increased the IL-5-specific
antibody titers, whereas a challenge with mIL-5 protein alone did not influence the anti-IL-5 antibody
titers. A similar endogenous-mimicry challenge experiment was carried out by Spohn et al. in mice that
had been vaccinated with IL-1β-VLP and were challenged with IL-1β, showing comparable results [25].
Although, a limitation of this study is that the challenge experiment was performed in vaccinated mice
only, and due to ethical reasons not in vaccinated client-owned horses, we want to highlight the fact
that in the absence of a vaccine booster, the anti-IL-5 antibody titers in horses declined. Nevertheless,
increased endogenous IL-5 levels are expected throughout the whole IBH season, indicated by enhanced
eosinophil levels even at the season end in placebo-vaccinated horses. Taken together, both independent
experiments in mice using different auto-proteins linked to VLP strongly indicate that the endogenous
IL-5 of the horse is not likely to boost and maintain the IL-5-specific antibody titers. Along that line,
a second safety requirement for B cells is the reversibility of the antibody response induced by the
vaccine. As described previously, horses that were vaccinated with eIL-5-CuMVTT in the first year,
then received a single booster immunization in the second year and one in the third year, had no
IL-5-specific antibodies shortly before the booster in the second and the third year, thus showing
the reversibility of vaccine-induced anti-IL-5 antibodies [7]. Besides the anti-IL-5 total IgG, the data
presented here confirm that the same is true for the IL-5-specific IgG subclasses; without the yearly
boost, the IL-5-specific antibody titers decrease to baseline, thus showing the antibody response indeed
was reversible. Therefore, the vaccine profile appeared safe from the B cell perspective.
Interestingly, the yearly booster of the vaccine induced similar levels of CuMVTT-specific antibodies
in the 1st, 2nd, and 3rd year with even a tendency towards higher levels for each year, whilst the
IL-5-specific IgG antibodies tended to show lower levels when compared to the initial vaccination year.
Nevertheless, at the same time, the horses had significantly decreased levels of eosinophils in the blood
and less clinical signs [7], clearly showing the effect of the vaccine. The decreased levels of the anti-IL-5
IgG antibodies in combination with the equally decreased eosinophil levels and reduced clinical signs
in follow-up years can be explained by the increased extravasation of the anti-IL-5 antibodies into the
target tissue skin and/or the presence of antibody-antigen complexes in the blood, and thus no longer
detectable by our ELISA method. Under physiological conditions, the antibody-antigen ICs are cleared
from the circulation, involving the innate immune system. As ICs can cause diseases in the kidney
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and liver when not properly cleared, we measured different parameters in blood indicating the health
status of both organs [34,35]. Here, no defects were found for either organ after treatment with the
eIL-5-CuMVTT throughout several consecutive vaccination periods. In addition, no effects were seen on
the general blood status. Also, as described above, therapeutic antibodies are expected to extravasate
to tissues such as the skin, and this will be no longer detectable in the serum. Other studies have shown
that the bioavailability of therapeutic antibodies—meaning the potential to extravasate from blood to
tissue—depends on several parameters of the antibody, such as the presence of glycostructures and the
absence of terminal sialic acids [36].
Furthermore, we suggest that the avidity of the polyclonal antibody response increases from
the vaccinations in the first year to the single booster vaccination in the second vaccination year,
whereas no further avidity increase is found from the second to the third year, suggesting an affinity
maturation of antibodies from the first to the second vaccination year, which does not further increase
in the following year (s).
The horse has seven IgG subclasses (IgG1-IgG7) [37] that differ in function, i.e., IgG4/7 and most
likely IgG1 protect against viral infections [38,39], while IgG3/5 has been linked to sensitization [40].
The main IgG subclasses following the vaccination with eIL-5-CuMVTT were IgG4/7 and IgG1, which
was to be expected as the vaccine appears as a virus to the immune system. We further showed that
the IgG4/7 subclass decreases more slowly over time as compared to IgG1, potentially due to the
increased bioavailability of the IgG1 subclass. The fact that the anti-IL-5 and the anti-CuMVTT antibody
responses are dominated by the same subclasses indicates that both responses were provided the same
T cell help, namely the CuMVTT-specific T cell help.
The most important T cell safety criterion when vaccinating against a self-protein is that the vaccine
does not by any means induce auto-reactive T cells. As discussed above, T cells undergo a very strict
negative selection during their development in order to eliminate any auto-reactive T cells. In order
to determine if any IL-5-reactive T cells were induced upon the vaccinations, PBMCs from horses
vaccinated for one, two, three, four, or five consecutive years were isolated and re-stimulated with
E. coli-eIL-5, HEK-eIL-5 and CuMVTT. Initially, we found low frequencies of IFN-γ+ CD4+ T cells when
the PBMCs from vaccinated horses were in vitro re-stimulated with E. coli-eIL-5. However, we also did
when re-stimulating with the irrelevant protein E. coli-mGM-CSF. The HEK-eIL-5 stimulation did not
lead to any IFN-γ production in the CD4+ and CD8+ T cells, confirming that the IFN-γ production in
the above-mentioned cases was due to E. coli traces. Additionally, there was no difference between the
cells from unvaccinated and vaccinated horses following the HEK-eIL-5 stimulation. At the same time,
the HEK-eIL-5-specific IgG was detected in the cell supernatant of resiquimod-stimulated PBMCs and
in the plasma of the same horses. This shows that the HEK-eIL-5 protein is relevant and should have
been able to stimulate the IL-5-specific peripheral T cells if there had been any. This finding correlates
well with the previously published data from Spohn et al., where IL-1β-reactive CD4+ T cells were not
detected in any of the vaccinated mice [25]. However, here we want to emphasize that we show the
lack of peripheral auto-reactive T cells upon vaccination with a self-protein in actual horse patients
and over several consecutive years. In contrast with the IL-5 auto-reactive T cells, we do expect to
induce CuMVTT-reactive T cells following the vaccinations in order to provide T cell help for the IgG
responses against both the CuMVTT and the IL-5. Indeed, the PBMCs from vaccinated horses showed
significant levels of CuMVTT-reactive CD4+ and, to a lesser extent, CD8+ T cells upon re-stimulation
with CuMVTT. This was seen both for the IFN-γ production and the proliferation.
5. Conclusions
Overall, the data presented here show that vaccination with a cytokine linked to a VLP is
a safe way to induce auto-antibodies with the induction of reversible, long-lived, neutralizing,
and not-endogen-induced IgG antibody responses, but at the same time without any induction of
auto-reactive T cells. The general health status of the horses is not compromised by the induction
of auto-antibodies, and the previously published reduction in the clinical signs of IBH leads, on the
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contrary, to an improved quality of life for the horses. This study comprises the first long-term B and T
cell safety analysis upon therapeutic vaccination with a self-antibody-inducing VLP-based vaccine.
Performed under field conditions and in a large animal suffering from a real disease, the current study
suggests that this vaccination strategy may be a safe replacement for costly monoclonal antibody
therapies in companion animals as well as in humans.
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Figure S3: Gating strategy for the proliferation of CD4+ and CD8+ T cells; Figure S4: No auto-proliferative CD4+ and
CD8+ T cells upon the in vitro re-stimulation of PBMCs, but specific IgGs upon resiquimod stimulated PBMCs. (A,B);
Figure S5: Additional liver and kidney parameters; Figure S6: Blood differential count and hematology.
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